Posted by Michael Wonder on 31 Mar 2022
ViiV Healthcare announces US FDA approval of Triumeq PD, the first dispersible single tablet regimen containing dolutegravir, a once-daily treatment for children living with HIV
30 March 2022 - The FDA approval of the first dispersible single tablet regimen containing dolutegravir increases age-appropriate treatment options for children living with HIV.
ViiV Healthcare has announced that the U.S. FDA has approved a new drug application for a dispersible tablet formulation of the fixed dose combination of abacavir, dolutegravir and lamivudine for the treatment of paediatric patients weighing 10 kg to <25 kg with human immunodeficiency virus type 1.
In addition, a supplemental new drug application has been approved for Triumeq tablet, lowering the minimum weight that a child with human immunodeficiency virus type 1 can be prescribed this medicine to 25 kgs from 40 kg.
